- Home
- LCTX vs FDBC Comparison
LCTX vs FDBC Comparison
Compare LCTX & FDBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- FDBC
- Stock Information
- Founded
- LCTX 1990
- FDBC 1902
- Country
- LCTX United States
- FDBC United States
- Employees
- LCTX N/A
- FDBC N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- FDBC Major Banks
- Sector
- LCTX Health Care
- FDBC Finance
- Exchange
- LCTX Nasdaq
- FDBC Nasdaq
- Market Cap
- LCTX 274.0M
- FDBC 234.2M
- IPO Year
- LCTX N/A
- FDBC N/A
- Fundamental
- Price
- LCTX $1.21
- FDBC $44.46
- Analyst Decision
- LCTX Strong Buy
- FDBC
- Analyst Count
- LCTX 4
- FDBC 0
- Target Price
- LCTX $4.25
- FDBC N/A
- AVG Volume (30 Days)
- LCTX 1.5M
- FDBC 5.7K
- Earning Date
- LCTX 08-12-2025
- FDBC 10-22-2025
- Dividend Yield
- LCTX N/A
- FDBC 3.54%
- EPS Growth
- LCTX N/A
- FDBC 49.33
- EPS
- LCTX N/A
- FDBC 4.10
- Revenue
- LCTX $10,914,000.00
- FDBC $84,975,000.00
- Revenue This Year
- LCTX N/A
- FDBC N/A
- Revenue Next Year
- LCTX $178.80
- FDBC N/A
- P/E Ratio
- LCTX N/A
- FDBC $11.01
- Revenue Growth
- LCTX 76.43
- FDBC 20.65
- 52 Week Low
- LCTX $0.37
- FDBC $37.00
- 52 Week High
- LCTX $1.31
- FDBC $61.21
- Technical
- Relative Strength Index (RSI)
- LCTX 59.58
- FDBC 57.21
- Support Level
- LCTX $1.15
- FDBC $44.39
- Resistance Level
- LCTX $1.31
- FDBC $47.49
- Average True Range (ATR)
- LCTX 0.08
- FDBC 1.34
- MACD
- LCTX 0.01
- FDBC 0.57
- Stochastic Oscillator
- LCTX 70.59
- FDBC 67.59
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About FDBC Fidelity D & D Bancorp Inc.
Fidelity D & D Bancorp Inc is a bank holding company. Through its wholly-owned state-chartered commercial bank subsidiary, The Fidelity Deposit and Discount Bank (the Bank), it offers a full range of traditional banking services. The Bank has a personal and corporate trust department and also provides alternative financial and insurance products with asset management services. Its primary market areas are Lackawanna, Luzerne and Northampton Counties, Pennsylvania. The company's primary deposit products are demand deposits and interest-bearing time, money market and savings accounts. It offers a full array of loan products to meet the needs of retail and commercial customers. Company includes segments: Commercial and Industrial, Commercial Real Estate, Consumer, Residential Real Estate.